S&P 5007,736.52▲1.8% Nasdaq26,584.99▲2.6% Dow54,085.88▲1.7% Russell 2K3,036.98▲1.9% 10-Yr4.63%−6bp VIX16.50+0.64 WTI$75.32▼6.2% Gold$4,133.60▲2.5% EUR/USD1.153▼0.1% BTC$64,715▲1.0% Nikkei63,755▼0.9%
At close · Tue, Aug 4, 2026
Daily Market Updates.

US Markets

Home›US Markets›Sectors›Novo Nordisk lost ground in GLP-1 weight-loss drugs to…

Novo Nordisk lost ground in GLP-1 weight-loss drugs to Eli Lilly

Reported · Written up by our desk · Sectors

MarketWatch frames Novo Nordisk’s GLP-1 weight loss dominance as having unraveled after Eli Lilly outmaneuvered it in the diet-drug market.

The outlet says the Danish company originally developed what it describes as the most lucrative new drug the world had ever seen, but lost control as competition intensified.

MarketWatch also poses the broader question of whether Europe can compete in the high-stakes global economy as GLP-1 demand and market share shift.

← Newer storyEnvoy Mortgage to buy MasonMac distributed retail assets

More like this

US MarketsLarry Ellison collected an estimated $579 million Oracle dividend check
US MarketsDisney considers free, ad-supported streaming to boost profitability
US MarketsAI credit markets face uncertain returns for investors, Andromeda warns
US MarketsStocks In Or Near Buy Range Catch Traders' Eye
US MarketsAI agents used stolen identities to attempt malicious code approvals

Sources

MarketWatchHow Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
MarketWatchHow Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.